Peer-reviewed veterinary case report
Long-term cyclosporine treatment controls itching in dogs with atopic
By RADOWICZ, STACEY N. & POWER, HELEN T.·Published in Veterinary Dermatology·2005·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Long‐term use of cyclosporine in the treatment of canine atopic dermatitis
- Species:
- dog
Plain-English summary
A group of 51 dogs with atopic dermatitis (a skin allergy) were treated with cyclosporine, an oral medication, for 6 to 30 months to see how well it controlled their symptoms. At the end of the study, about half of the dogs still needed cyclosporine to manage their itching and skin issues, while the other half either improved enough to stop treatment or didn’t respond well. Some dogs experienced side effects like lab abnormalities or skin changes, but most owners were satisfied with the treatment and reported no major issues. Cyclosporine can be effective for managing atopic dermatitis in dogs, but ongoing treatment needs can vary.
People also search for: dog skin allergy treatment · cyclosporine for dogs · atopic dermatitis in dogs · dog itching medication · side effects of cyclosporine in dogs
Abstract
Abstract This retrospective study of 51 dogs with atopic dermatitis (AD) treated with cyclosporine (CsA) for a minimum of 6 months assessed the frequency of dosing and the need for continual treatment to control clinical signs. The study evaluated both medical records and information supplied by the owners in the form of written questionnaires and telephone follow‐up. Laboratory parameters, possible adverse effects and owner satisfaction were assessed. The dose of CsA was 5 mg/kg orally per day and dogs received CsA for 6–30 months. At the conclusion of the study period, 28 dogs (55%) needed ongoing CsA to control clinical signs of AD: 8 (15%) received CsA 2–3 days per week, 10 (20%) 4–5 days per week, and 10 (20%) daily. CsA was discontinued in 23 dogs (45%) after 6–24 months due to either a limited response (22%) or after achieving a clinical response (24%). The results suggest that some dogs with AD treated with CsA may not require daily or even ongoing treatment to control clinical signs. Laboratory abnormalities were detected in 13 dogs (25%) during their CsA treatment. Two dogs developed oral growths and three developed hirsuitism. Forty owners (78%) reported no adverse events in their dogs during the treatment period. Thirty‐six owners (71%) were satisfied with CsA as treatment for their atopic dog.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/j.1365-3164.2005.00435.x